Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately ...

Will Sepracor change its name to "Aptiom" on April 1? That's the speculation on CafePharma, where one anonymous commenter notes that the maker of the sleeping pill Lunesta, whose moth-filled ads ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

If at first you don’t succeed, cut jobs. That’s what Sepracor , the drug maker, is planning to do as part of an initiative designed to boost its earning guidance. The Marlborough, Mass.- ...

Despite relatively uneventful earnings, Sepracor was in good health as it announced to investors that it was joining the Canadian market and will now be able to collect royalties on the generic ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., an Osaka, Japan-based pharmaceutical company, announced today that Sepracor's name will be changed to Sunovion Pharmaceuticals Inc. in the United ...

NEW YORK (MarketWatch) -- Sepracor Inc. sepr said Thursday it won't be able to file its Form 10-Q for the quarter ended June 30 until it has "substantially completed" the previously disclosed ...

Sepracor Inc., a U.S. subsidiary of Japanese drug maker Dainippon Sumitomo Pharma Co. Ltd. (DSP), is changing its name to Sunovion Pharmaceuticals Inc. in the U.S., which will go into effect befor ...

NEW YORK Marlborough, Mass.-based pharmaceutical company Sepracor has shelled out $50 million for a Canadian drug manufacturer, Sepracor announced Tuesday. Sepracor bought Canada’s Oryx ...

MARLBOROUGH, Mass. (CBS.MW) - Sepracor Inc. rose from obscurity to become a Wall Street darling in the late '90s as investors bet that the company could capture a big piece of the lucrative market ...

Sepracor Inc., badly hurt by the Food and Drug Administration's rejection last year of its allergy drug, Soltara, now has another shot at success with a hot new insomnia medication. The FDA is ...

Sepracor Inc. will cut 20% of its permanent workforce and refine its business model amid challenging economic conditions despite swinging to a fourth-quarter profit that topped Wall Street ...